Personally, I’d much rather that Generex only focused on advancing the Ii-Key Covid vaccine and weren’t issuing so many shares for build ups in Arizona or anything for Excellagen. I don’t mean to disrespect their chosen path, but waiting until the IND was a past event and the IPO was successful would have afforded the company with far better avenues for gaining capital to more quickly advance in Arizona or elsewhere. Share prices don’t take care of themselves. They do get beat down by the company raising money at the worst time as they have too wide of a focus. So, the only things I want to hear about are the IND being approved, Phase I beginning, and success on the NGIO IPO.